Background & relevance

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Chemotherapy has been the mainstay of treatment and shifted from the adjuvant to neoadjuvant setting in early-stage disease. Promising new agents are on the horizon.